Efficacy and Safety of Bevacizumab in Chinese Patients with Metastatic Colorectal Cancer

Objective: To evaluate the efficacy and safety of bevacizumab in the treatment of patients with metastatic colorectal cancer (mCRC). Methods: In a single-center, observational study of 91 Chinese patients with mCRC who received bevacizumab in combination with chemotherapy was conducted. Objective re...

Full description

Saved in:
Bibliographic Details
Published in:Asian Pacific journal of cancer prevention : APJCP 2014, Vol.15 (16), p.6559-6564
Main Authors: Zhu, Li-Ming, Zhao, Ya-Zhen, Ju, Hai-Xing, Liu, Lu-Ying, Chen, Lei, Liu, Bi-Xia, Xu, Qi, Luo, Cong, Ying, Jie-Er, Yang, Yun-Shan, Zhong, Hai-Jun
Format: Article
Language:Korean
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective: To evaluate the efficacy and safety of bevacizumab in the treatment of patients with metastatic colorectal cancer (mCRC). Methods: In a single-center, observational study of 91 Chinese patients with mCRC who received bevacizumab in combination with chemotherapy was conducted. Objective response rates (ORRs), progression-free survival (PFS), overall survival (OS) and adverse events were recorded, and the relationships between various clinical factors and PFS or OS were evaluated by Cox proportional hazards models. Results: Treatment with bevacizumab and chemotherapy was effective and tolerable. Univariate analysis showed that PFS and OS were significantly associated with the Eastern Cooperative Oncology Group performance status (ECOG-PS) score, duration of bevacizumab exposure, and whether chemotherapy was continued after discontinuation of bevacizumab treatment. A multivariate analysis showed that the duration of bevacizumab exposure and whether chemotherapy was continued after discontinuation of bevacizumab were independent prognostic factors for PFS and OS. Conclusion: In Chinese mCRC population, the shorter the duration of exposure to bevacizumab and chemotherapy, the worse the prognosis is.
ISSN:1513-7368
2476-762X